‪Kim Papp and K Papp and K A Papp and Kim Alexander Papp and K Alexander Papp‬

Navedeno

	Vse	Od leta 2020
Navedbe	55068	22181
indeks h	108	68
indeks i10	329	232

4800

2400

1200

3600

20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025211 308 519 664 906 1092 1277 1256 1226 1741 1934 2393 2476 3160 3670 4064 4302 4403 4769 4450 3940 3744 701

Javni dostop

Prikaži vse

17 člankov

2 članka

na voljo

ni na voljo

Na podlagi zahtev v povezavi s financiranjem

Soavtorji

Andrew BlauveltInvestigator, Oregon Medical Research CenterPreverjeni e-poštni naslov na oregonmedicalresearch.com
Christopher E.M. GriffithsProfessor of Dermatology, University of ManchesterPreverjeni e-poštni naslov na manchester.ac.uk
Alexa B. KimballProfessor, Harvard Medical SchoolPreverjeni e-poštni naslov na alumni.princeton.edu
Melinda GooderhamDermatologist, SKiN Centre for Dermatology; Assistant Professor, Queen's University; InvestigatorPreverjeni e-poštni naslov na centrefordermatology.com
Poulin YCentre dermatologique, Laval universityPreverjeni e-poštni naslov na bellnet.ca
Carle PaulUniversité Toulouse 3 Paul SabatierPreverjeni e-poštni naslov na chu-toulouse.fr
HOWARD L SOFENDavid Geffen UCLA School of MedicinePreverjeni e-poštni naslov na g.ucla.edu
Lluis PuigHead, Department of Dermatology, Hospital de la Santa Creu i Sant PauPreverjeni e-poštni naslov na santpau.cat
Eric SimpsonFrances J. Storrs Medical Dermatology Professor, Dermatology, OHSUPreverjeni e-poštni naslov na ohsu.edu
James KruegerProfessorPreverjeni e-poštni naslov na rockefeller.edu
Peter van de KerkhofradboudPreverjeni e-poštni naslov na radboudumc.nl
Jacek SzepietowskiWrocław Medical UniversityPreverjeni e-poštni naslov na umed.wroc.pl
April W. Armstrong, MD MPHProfessor and Chief of Dermatology, University of California Los Angeles (UCLA)Preverjeni e-poštni naslov na post.harvard.edu
Chih-ho HongClinical Assistant Professor, University of British ColumbiaPreverjeni e-poštni naslov na mail.ubc.ca
Rod Sinclair MBBS, MD, FACDProfessor Medicine (Dermatology) University of Melbourne, Epworth Hospital and Sinclair DermatologyPreverjeni e-poštni naslov na epworthdermatology.com.au
Ahmed M. Soliman, MS, PhDDirector, Health Economics and Outcomes Research, AbbVie Inc.Preverjeni e-poštni naslov na abbvie.com
Neil KormanProfessor of Dermatology, Case Western Reserve UniversityPreverjeni e-poštni naslov na case.edu
Akimichi MoritaNagoya City UnivesityPreverjeni e-poštni naslov na med.nagoya-cu.ac.jp
Lawrence EichenfieldProfessor of Dermatology and Pediatrics, University of California, San DiegoPreverjeni e-poštni naslov na rchsd.org
Juan Gomez-ReinoUNIVERSITY OF SANTIAGO, USC and FUNDACION IDIS, HOSPITAL CLINICO UNIVERSITARIO, SANTIAGO, SPAINPreverjeni e-poštni naslov na sergas.es

Spremljaj

Kim Papp and K Papp and K A Papp and Kim Alexander Papp and K Alexander Papp

Probity Medical Research

Preverjeni e-poštni naslov na probitymedical.com

clinical development clinical trial design disease severity measures bias and error in assessments evaluation of clinical tr


Naslov Razvrsti po navedbah Razvrsti po letniku Razvrsti po naslovu	Navedeno Navedeno	Leto
Secukinumab in plaque psoriasis—results of two phase 3 trials RG Langley, BE Elewski, M Lebwohl, K Reich, CEM Griffiths, K Papp, ... New England Journal of Medicine 371 (4), 326-338, 2014	2350	2014
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo … CL Leonardi, AB Kimball, KA Papp, N Yeilding, C Guzzo, Y Wang, S Li, ... The Lancet 371 (9625), 1665-1674, 2008	2039	2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo … KA Papp, RG Langley, M Lebwohl, GG Krueger, P Szapary, N Yeilding, ... The Lancet 371 (9625), 1675-1684, 2008	1760	2008
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial K Reich, FO Nestle, K Papp, JP Ortonne, R Evans, C Guzzo, S Li, ... The Lancet 366 (9494), 1367-1374, 2005	1350	2005
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial S Tyring, A Gottlieb, K Papp, K Gordon, C Leonardi, A Wang, D Lalla, ... The Lancet 367 (9504), 29-35, 2006	1338	2006
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded … A Blauvelt, M de Bruin-Weller, M Gooderham, JC Cather, J Weisman, ... The Lancet 389 (10086), 2287-2303, 2017	1314	2017
Brodalumab, an anti–interleukin-17–receptor antibody for psoriasis KA Papp, C Leonardi, A Menter, JP Ortonne, JG Krueger, G Kricorian, ... New England Journal of Medicine 366 (13), 1181-1189, 2012	1164	2012
Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial A Menter, SK Tyring, K Gordon, AB Kimball, CL Leonardi, RG Langley, ... Journal of the American Academy of Dermatology 58 (1), 106-115, 2008	1102	2008
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis New England Journal of Medicine 362, 118-128, 2010	1060	2010
Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis KB Gordon, A Blauvelt, KA Papp, RG Langley, T Luger, M Ohtsuki, ... New England Journal of Medicine 375 (4), 345-356, 2016	994	2016
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe … A Blauvelt, KA Papp, CEM Griffiths, B Randazzo, Y Wasfi, YK Shen, S Li, ... Journal of the american academy of dermatology 76 (3), 405-417, 2017	940	2017
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials CEM Griffiths, K Reich, M Lebwohl, P Van De Kerkhof, C Paul, A Menter, ... The Lancet 386 (9993), 541-551, 2015	916	2015
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) JH Saurat, G Stingl, L Dubertret, K Papp, RG Langley, JP Ortonne, ... British Journal of Dermatology 158 (3), 558-566, 2008	913	2008
Phase 3 studies comparing brodalumab with ustekinumab in psoriasis M Lebwohl, B Strober, A Menter, K Gordon, J Weglowska, L Puig, K Papp, ... New England Journal of Medicine 373 (14), 1318-1328, 2015	893	2015
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction KA Papp, S Tyring, M Lahfa, J Prinz, CEM Griffiths, AM Nakanishi, R Zitnik, ... British Journal of Dermatology 152 (6), 1304-1312, 2005	876	2005
Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty‐four–week efficacy and safety … A Kavanaugh, I McInnes, P Mease, GG Krueger, D Gladman, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2009	824	2009
Two phase 3 trials of adalimumab for hidradenitis suppurativa AB Kimball, MM Okun, DA Williams, AB Gottlieb, KA Papp, CC Zouboulis, ... New England Journal of Medicine 375 (5), 422-434, 2016	776	2016
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological … C Ritchlin, P Rahman, A Kavanaugh, IB McInnes, L Puig, S Li, Y Wang, ... Annals of the rheumatic diseases 73 (6), 990-999, 2014	766	2014
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy … K Papp, K Reich, CL Leonardi, L Kircik, S Chimenti, RGB Langley, CC Hu, ... Journal of the American Academy of Dermatology 73 (1), 37-49, 2015	719	2015
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis A Menter, SR Feldman, GD Weinstein, K Papp, R Evans, C Guzzo, S Li, ... Journal of the American Academy of Dermatology 56 (1), 31. e1-31. e15, 2007	679	2007

Sistem trenutno ne more izvesti postopka. Poskusite znova pozneje.

Članki 1–20

Št. navedb na leto

Podvojene navedbe

Združene navedbe

Dodajanje soavtorjevSoavtorji

Spremljaj

Navedeno

Soavtorji